Tandem Diabetes Care (TNDM) Earnings Date & Reports

Key Takeaways

• Worldwide sales rose 14% year over year to $283.7 million, beating analyst consensus estimates.
• Net loss narrowed to $7.1 million, or $0.10 per share, from $21.2 million, or $0.31 per share, a year earlier.
• Gross margin reached 57%, up 270 basis points compared to the third quarter of 2025.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed to $18.0 million, or 6% of sales, versus $2.8 million a year ago.
• The company reaffirmed full-year 2026 sales guidance of $1.065 billion to $1.085 billion.
• Worldwide pump shipments totaled roughly 33,000, including nearly 23,000 in the United States.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional TNDM pages on Tickeron.
• Looking for automated trade ideas? Explore Trending AI Robots to see AI-driven strategies in action.

Earnings Context and Why It Matters

Tandem Diabetes Care's third-quarter results arrived at a pivotal moment in its business-model transformation. The company is shifting U.S. sales toward a pay-as-you-go (PayGo) pharmacy channel, which reduces upfront pump revenue but is designed to improve long-term economics and expand patient access. Investors are closely watching whether margin gains and international growth can offset the near-term revenue headwinds from this transition. With the stock having trailed the broader market earlier in 2026, this report was also a key test of whether Tandem's profitability roadmap is on track.

Reported Results

Tandem Diabetes Care reported third quarter 2026 worldwide sales of $283.7 million, up 14% from $249.3 million in the prior-year period, exceeding consensus estimates of roughly $264 million. U.S. sales rose 9% to $191.0 million, while international sales jumped 26% to $92.6 million.

The company posted a net loss of $7.1 million, or $0.10 per share, a meaningful improvement from a net loss of $21.2 million, or $0.31 per share, a year ago. The per-share result came in well ahead of the consensus estimate of a larger loss.

Gross margin expanded to 57%, up 270 basis points, while the operating loss narrowed to $2.4 million from $22.9 million. Adjusted EBITDA reached $18.0 million, or 6% of sales, compared with $2.8 million, or 1% of sales, in the year-ago quarter.

Management reaffirmed full-year 2026 guidance, including sales of $1.065 billion to $1.085 billion and gross margin of approximately 56% to 57% of sales.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you want to complement your own research with data-driven market scanning, consider exploring the AI Screener.

Market Reaction and Investor Sentiment

Shares moved higher following the report, reflecting investor enthusiasm for the revenue beat and the continued margin expansion. The sharp narrowing of the net loss and the rebound in adjusted EBITDA reinforced confidence that Tandem's PayGo transition and international go-direct strategy are beginning to deliver improved profitability. The reaffirmed full-year guidance also removed a key source of uncertainty heading into the fourth quarter.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should watch several themes tied to Tandem's transformation. First, the pace of PayGo pharmacy adoption remains central. Management reported that about 15% of U.S. sales now flow through the pharmacy channel, with formulary coverage reaching approximately 50% of U.S. lives. How quickly this mix shifts will influence near-term revenue timing and long-term gross margin.

Second, international expansion is gaining momentum. The t:slim X2 system's compatibility with the Abbott FreeStyle Libre 3 Plus sensor is now available in 11 international markets, and Tandem Mobi is available in 12 countries. Continued rollout into new direct markets could support revenue growth, though transitions away from distributors can create temporary headwinds.

Finally, cost discipline and product mix will determine whether Tandem sustains its margin trajectory. Management has signaled an expectation that gross margins could scale toward the upper end of guidance as direct-channel pricing and higher Mobi volumes take hold. Balancing these drivers against competitive pressures in automated insulin delivery will be key for investors tracking the next several quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations